Загрузка...
Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries
BACKGROUND: The putative benefits of cinacalcet therapy for management of secondary hyperparathyroidism (SHPT) are thought to be most manifested when patients are taking it consistently and as prescribed. Real-world descriptions of cinacalcet prescription discontinuation and reinitiation in European...
Сохранить в:
| Опубликовано в: : | BMC Nephrol |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6518810/ https://ncbi.nlm.nih.gov/pubmed/31088377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-019-1355-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|